Bašić, J

Damjanov, N

Lazarević, D

Sušić, G

Vojinović, J

English

PubMed

Damjanov N

Sušić G

Vojinović J

Lazarević D

Bašić J

Directory of Open Access Journals

Pediatric Rheumatology

DNase I levels and disease outcome in JIA patients treated with etanercept

D Lazarević

J Vojinović

G Sušić

N Damjanov

J Bašić

Crossref

Springer - Publisher Connector

POSTER PRESENTATION Open Access
DNase I levels and disease outcome in JIA
patients treated with etanercept
D Lazarević1*, J Vojinović1, G Sušić2, N Damjanov2, J Bašić3
From 18th Pediatric Rheumatology European Society (PReS) Congress
Bruges, Belgium. 14-18 September 2011
Background
Failure to efficiently degrade the DNA of apoptotic cells
activates innate immunity, by induction of TNFά and
IFNb production, causing chronic arthritis. If deficient,
DNase I could leed to accumulation of undigested DNA
which induce activation of phagocytes and production
of proinflammatory cytokines, notably TNF.
Aim
Disease outcome in JIA patients after one year of treat-
ment with TNFά therapy and their DNase I levels.
Methods
The study was performed in 25 JIA patients who
donated paired serum samples prior and one year after
continous etanercept therapy. Basic clinical data (six
core set variables defined in ACR PEDI outcome score)
were recorded along with alkalyne DNase I serum levels
using the method where acid soluble nucleotides are
determined spectrophotometrically at 260 nm. Treat-
ment schedule of etanercept was 0,4mg/kg body weight
subcutaneously twice weekly.
Results
JIA patients mean age was 14,7+/-4,22 and disease dura-
tion is 6,59+/- 2,76. Disease type distribution was 8%
systemic, 28% polyarticular RF-, 25% polyarticular RF+,
17% ERA and 21% extended oligoarticular JIA. Summary
of data results prior and after anti TNFά therapy: ESR
26,88 vs.15,52 (p<0,01); patientVAS 40,24 vs.24,40
(p<0,05); physicianVAS 38,08 vs.10,32 (p<0,01); CHAQ
0,674 vs.0,375 (p<0,01); LOM 15,52 vs. 11,68 (NS); AA
9,24 vs.2,64 (p<0,01). DNase I levels were significantly
lower prior (2.934 U/l) compared to values after one
year therapy (4,184 U/l; p<0,01). We have found correla-
tion between DNase I levels and AA (r=-0,993 p<0,5)
and other clinical outcome variables prior and after
therapy.
Conclusion
JIA patients with active disease have decreased DNase I
levels. Our results indicate significant increase of DNase
I in the sera of JIA patients after one year of anti TNFά
therapy which was associated to the disease clinical
improvement.
Author details
1Department of Pediatric Rheumatology, University Clinical Center Niš,
Serbia. 2Institute of Rheumatology, Belgrade, Serbia. 3Department of
Biochemistry, Faculty of Medicine, Niš, Serbia.
Published: 14 September 2011
doi:10.1186/1546-0096-9-S1-P171
Cite this article as: Lazarević et al.: DNase I levels and disease outcome
in JIA patients treated with etanercept. Pediatric Rheumatology 2011 9
(Suppl 1):P171.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
* Correspondence: lazarevic.gaga@gmail.com
1Department of Pediatric Rheumatology, University Clinical Center Niš, Serbia
Full list of author information is available at the end of the article
Lazarević et al. Pediatric Rheumatology 2011, 9(Suppl 1):P171
http://www.ped-rheum.com/content/9/S1/P171
© 2011 Lazarevićć et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.


file:///data/remote/core/dit/data/Springer-OA/pdf/497/aHR0cDovL2xpbmsuc3ByaW5nZXIuY29tLzEwLjExODYvMTU0Ni0wMDk2LTktUzEtUDE3MS5wZGY=.pdf

DNase I levels and disease outcome in JIA patients treated with etanercept

Abstract

Similar works

Full text

Available Versions

Directory of Open Access Journals

Crossref

Springer - Publisher Connector

Springer - Publisher Connector